Patent · US Active

Salt and polymorphs of a DPPIV inhibitor

US7772264B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Stefan Abrecht · Duggingen, CH
Andre Bubendorf · Uffheim, FR
Stephan Goetzoe · Muttenz, CH
Olaf Grassmann · Soest, DE
Francois Montavon · Delémont, CH
Regina Moog · Glückstadt, DE
Franziska E. Rohrer · Riehen, CH
Armin Ruf · Glückstadt, DE
Michelangelo Scalone · Birsfelden, CH
Urs Schwitter · Reinach, CH
Shaoning Wang · Basel, CH

Key dates

Filing date	Mar 16, 2006
Grant date	Aug 10, 2010
Priority date	—
Expiry date	Mar 2, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is concerned with (S)-1-{[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile mesylate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.